Abstract
Systemic infections, especially in patients with chronic diseases, result in sepsis: an explosive, uncoordinated immune response that can lead to multisystem organ failure with a high mortality rate. Sepsis survivors and non-survivors oftentimes have similar clinical phenotypes or sepsis biomarker expression upon diagnosis, suggesting that the dynamics of sepsis in the critical early stage may have an impact on these opposite outcomes. To investigate this, we designed a within-subject study of patients with systemic gram-negative bacterial sepsis with surviving and fatal outcomes and performed single-cell transcriptomic analyses of peripheral blood mononuclear cells (PBMC) collected during the critical period between sepsis recognition and 6 hours. We observed that the largest sepsis-induced expression changes over time in surviving versus fatal sepsis were in CD14+ monocytes, including gene signatures previously reported for sepsis outcomes. We further identify changes in the metabolic pathways of both monocytes and platelets, the emergence of erythroid precursors, and T cell exhaustion signatures, with the most extreme differences occurring between the non-sepsis control and the sepsis non-survivor. Our single-cell observations are consistent with trends from public datasets but also reveal specific effects in individual immune cell populations, which change within hours. In conclusion, this pilot study provides the first single-cell results with a repeated measures design in sepsis to analyze the temporal changes in the immune cell population behavior in surviving or fatal sepsis. These findings indicate that tracking temporal expression changes in specific cell-types could lead to more accurate predictions of sepsis outcomes. We also identify molecular pathways that could be therapeutically controlled to improve the sepsis trajectory toward better outcomes.
Summary sentence Single cell transcriptomics of peripheral blood mononuclear cells in surviving and fatal sepsis reveal inflammatory and metabolic pathways that change within hours of sepsis recognition.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the UCR School of Medicine (to AG and MGN), the Dean Innovation Fund (to JB and MGN), and the National Institutes of Health (NIAID, R21AI37830 and R01AI153195 to MGN). The data from this study was generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human peripheral blood was collected from non-sepsis donors from the Riverside Free Clinic and septic patients with signed informed consent and approval of the University of California, Riverside (UCR, #HS-17-707), and Riverside University Health System (RUHS, #1024190-3) Institutional Review Board. Sepsis patient enrollment was performed according to the following inclusion criteria: 1/Admission to Intensive Care Unit; 2/Age greater than or equal to 18 years old; 3/Suspected or confirmed infection; 4/qSOFA score ≥ 2 (qSOFA variables: altered mentation [GCS ≤ 13], systolic blood pressure < 100 mmHg and respiratory rate > 22 breaths/minute) and/or; 5/Lactate greater than or equal to 2.0 mmol/L and on vasopressor therapy to maintain MAP > 65 mmHg after 30 mL/kg intravenous fluid bolus.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data have been deposited with the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) with the GEO accession, GSE167363. Other supporting raw data are available from the corresponding author upon request. Source data are provided with this paper.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167363